Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.

Journal of managed care & specialty pharmacy·2026
Same author

Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia Gravis.

JAMA network open·2026
Same author

Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis.

Medicine·2026
Same author

ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals.

Frontiers in neurology·2026
Same author

Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Appropriate use of steroids for patients with generalized Myasthenia Gravis: an international Delphi study.

Therapeutic advances in neurological disorders·2025
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Myasthenia gravis.

Nicholas J Silvestri1, Gil I Wolfe

  • 1Department of Neurology, State University of New York at Buffalo, Buffalo General Medical Center, Buffalo, New York 14203, USA.

Seminars in Neurology
|November 3, 2012
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) is a neuromuscular junction disorder causing fatigable weakness. Treatments include acetylcholinesterase inhibitors, immunosuppressants, and thymectomy, with new immunotherapies under investigation.

Related Experiment Videos

Last Updated: May 17, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Myasthenia gravis (MG) is a prevalent neuromuscular junction disorder.
  • Characterized by fatigable weakness, often starting with ocular symptoms like ptosis and diplopia.
  • Disease generalization affects bulbar, respiratory, limb, and neck muscles in two-thirds of patients.

Purpose of the Study:

  • To provide a comprehensive overview of myasthenia gravis.
  • To discuss the underlying pathophysiology, clinical presentation, and diagnostic markers.
  • To review current and emerging therapeutic strategies for MG management.

Main Methods:

  • Review of existing literature on myasthenia gravis.
  • Analysis of prevalence, clinical manifestations, and immunological findings.
  • Summary of established and investigational treatment modalities.

Main Results:

  • Most generalized MG patients have antibodies against nicotinic acetylcholine receptors.
  • A subset of generalized MG patients exhibit antibodies to muscle-specific receptor tyrosine kinase (MuSK).
  • Acetylcholinesterase inhibitors are a primary therapy, alongside immunosuppressants like corticosteroids and azathioprine.

Conclusions:

  • MG is an immune-mediated NMJ disorder with diverse clinical presentations.
  • Management involves symptomatic treatment, immunosuppression, and potentially thymectomy.
  • Ongoing research focuses on novel immunotherapies, including complement inhibitors and agents like rituximab.